Wall Street can’t keep ignoring this cannabis market that’s four times the size of the U.S.

Cannabis was once the Wild West.

But now it’s ballooned into a global opportunity.

As we speak, cannabis is set to get the green-light around the world, and an entire class of cannabis companies has positioned themselves to profit from this worldwide economic phenomenon.

As I’ve previously discussed before, much of the attention on cannabis has been on the opportunity within the U.S.

And this singular focus isn’t surprising. Given the revenues realized in states where cannabis is legal, you can see how the value of the U.S. cannabis market could exceed $1 trillion once marijuana is fully legalized.

That’s because a fully legal U.S. market could reach $100 billion in annual sales.

From where legal revenues currently sit, that requires revenue growth of 80% per year to get there. Companies with revenues growing that fast can easily trade at 10 times sales. And 10 times $100 billion is $1 trillion.

But the end of cannabis prohibition is a global phenomenon, and this is how it will drive far more wealth creation than is possible in U.S. markets alone.

The Markets Miss the Point, So Far

Even if we focus on just the 30 richest countries in the world, the U.S. represents 40% of that buying power. Assuming a market limited to only these countries, you’re looking at a global market worth nearly $2.4 trillion ($1 trillion is 40% of $2.4 trillion).

And that doesn’t include the big Latin American markets like Chile, Argentina, or even Brazil.

It leaves out large Eastern European countries like Poland or gateway-to-the-East Turkey, with 120 million people between them.

And while populations of rich Asian countries like Singapore, Japan, and Korea count, the three billion people in China, India, Indonesia, and Thailand don’t even figure in the opportunity.

Add in the rest of the world and the U.S. contribution to spending shrinks to 25%.

That puts a global market valued at $4 trillion within easy reach. And even a modest share of the global cannabis trade will mean billions in revenues and vaulting stock prices for those companies best positioned to capture those sales.

But the way the market is pricing these international cannabis plays, it’s clear they don’t yet see the whole picture.

Three Ways to Play Globalization

You know all about PharmaCielo (OTC: PHCEF). This mega-grower, based in Colombia, has the capacity to grow more cannabis than can be grown in all of Canada. It actually grows pot where pot should be grown!

And its international footprint already covers half the Southern Hemisphere.

But based on its valuation, the market is only giving it credit for 0.02% of future global sales – a mere sliver of tomorrow’s cannabis market.

Khiron Life Sciences (OTC: KHRN, OTC: KHRNF) is possibly another soon-to-be international heavyweight. It has access to over half-a-million patients, and Vicente Fox, former Mexican president and Coca-Cola Mexico CEO is on its board. Its expansion plans and connections will give it a huge international footprint.

And I told Cannabis Profits Daily readers a little about International Cannabis Corp. (CSE: WRLD, OTC: WLDCF) on Wednesday. This lean and hungry multi-national cannabis company has operations on three continents. With just a small management team, this tiny company is on an acquisition spree, quietly laying the groundwork for a truly global cannabis enterprise.

Know that markets are massively undervaluing these – and many other – global cannabis plays.

But they won’t for long, and with our NICILytics database, you can stay ahead of the game.

And make sure that you’re on top of the latest holdings in the Cannabis IPO Insider’s portfolio.

With the slew of IPOs set to come down the pike over the next few months, you’ll want to make certain you’re in those names that will profit once the global cannabis boom before the inevitable becomes obvious.

I told you recently that the IPO market tone is changing for the better, so I’ll also be sending out an alert soon on our current positions we want to add more to.

Greg Miller
Executive Director, National Institute for Cannabis Investors


Montel Williams and His Incredible Cannabis Journey

You may know Williams as a successful TV personality.

However, you may not know that he is also a big supporter of cannabis legalization. He has multiple sclerosis, a disease that produces burning sensations from his head to his toes.

He’s been using cannabis since 1999, and with his first-hand experience, he’s launched his own line of cannabis products through Lenitiv Labs.

The company carries CBD and THC products throughout California.

Soon, his products will be available in dispensaries in Nevada, San Diego, and Oregon.

Williams truly has great insight about the cannabis industry, so we hope you enjoy this interview!


Comments

10 responses to “Look Here for the World’s Largest Market for Pot”

  1. Morning Greg I hope you had a great holiday. I know this market is going to eventually change and hopefully for the better and more sooner than later. But Greg we are nearing the point where it is time to stop talking about what is going to happen to our stocks in our portfolios and we as your students/members start seeing it!!! It’s like a weather forecast you can’t keep calling for sunshine and all we are seeing storms. It makes you look like you don’t know what your talking about. At either rate I hope you have a great day thank you for the information. Much success to all of us in the future!!!1

  2. I can not find the link to the interview with Montel. And I also have a question about the portfolios, and NikiLytics, why do we not show both the Canadian or US and the OTC information? Just sayin, my portfolios do not match the NICI portfolios, it makes me feel like I have done something wrong because I can’t buy Canadian or didn’t. I also have not into any of my positions at the price you have, and sometimes close but all the time over. You also throw me of when you say don’t pay more than xxx, When I go in to buy the price is always more than that, sometimes close but more, Just sayin. I down 18000 from April, makes you wonder, Just sayin.

    • The reason your prices don’t correspond exactly to the portfolio’s prices is that you buy at a certain price and that price remains regardless of whether the actual value is higher or lower than what you bought it at. The price given in the portfolio is the current price or maybe the daily closing price, so it will change as the market changes.
      As for what to do when a buy-up-to price is given, set a limit price instead of buying at market. You can set a limit that will expire in 1 day or you can set it as “good until cancelled.” Most brokers will limit that to 90 days and if you want it to run longer, you have to reset it. You can cancel it at any time in that time frame and you won’t be charged a commission unless the stock is actually bought for you (at least that’s how Schwab does it.) One thing to be aware of is that if the stock is really sinking, you may buy a stock for $5.00 that falls to $4.50. That happens, but if you’ve got a good stock, chances are it will go back up- probably not today, but hopefully sooner rather than later!
      If you don’t understand my explanation of setting a limit order, call your broker or Google “setting a limit order.” It’s not hard!

  3. Greg, I am a subscriber to the Cannabis Investors Reports and am an investor your model portfolio. Since I am aware that the “Vault” has 1 to 5 ratings on number of cannabis companies which are not available to all members, would you be willing to consider adding your ratings on the stocks in the model portfolio? If they all are rated “5”, a comment to that effect would suffice. Thank you for your consideration in this regard.

  4. Thinking about buying a cannabis Roth IRA,if you were to buy one are two companies,what would you buy? Thx

  5. Greg with your influence could you find out when ICC International Cannabis will report this quarter revenue…. thanks for your service to your investors.

  6. I just read the article by Danny Brody concerning the FDA and CBD stocks. It is true that CBD oil has not had double blind studies to check the efficacy of the treatment for each and every disease that it is purported to help. However, no one has really come up with a danger signal that would make the medical community wary of treatment. Thus, the treatment for certain diseases that anecdotally have helped others is not circumspect.
    If people, I know, have tried replacing there conventional medication with CBD oil, It appears the only danger is that it did not work.

    Thus, for example, if a rheumatoid arthritis patient was trying to get off of methotrexate and on to CBD oil, I doubt if the doctor or the patient would be leery of trying the CBD oil. Instead of waiting for 10 years for the double blind Placebo study comparing Methotrexate and other prescription drugs to CBD oil…it appears that there does not seem to be a reason for not trying.
    I am a dentist and I have personally seen 2 of my patients come off of methotrexate, ibuprofen, Tylenol because of protein urea (it would only be a matter of time before kidney failure) and on to CBD oil and have little to no pain with only the CBD oil… Now, the only entity we have to fight is Big Pharma… So, in the southern vernacular “Bless your Heart Big Pharma…
    ( and for those of you that live in the north….” Bless Your Heart”…is not a compliment!!
    To make matters even better, my youngest son sells CBD oil for a vertically integrated company, GenCanna, Winchester Ky) (from seed to harvest to processing and bottling) His sales team is making labels for many physicians who are selling it in their office! Again, “Bless your heart big Pharma”!
    Marshall J. Ney DMD

Leave a Reply

Your email address will not be published. Required fields are marked *